Saudi regulator approves eight advanced cell and gene therapies

A review of clinical trial registrations and health agency records shows approvals covering CAR-T, CRISPR, and viral vector treatments through 2025.

The Saudi Food and Drug Authority cleared eight advanced therapy medicinal products through 2025, expanding market authorization for cell and gene treatments across the kingdom, according to a review of regulatory records and clinical trial registrations.¹

The cleared treatments include chimeric antigen receptor T-cell therapies, adeno-associated virus vectors, and therapies based on clustered regularly interspaced short palindromic repeats gene editing.¹ The authorizations reflect alignment between domestic oversight and international evaluation standards for complex biologic treatments, according to a research team led by Mohammed H AlMuhanna that examined regulatory filings and trial databases spanning from 2010 to 2025.¹

Advanced therapy medicinal products, commonly designated as ATMPs, encompass gene therapies, somatic cell therapies, and tissue-engineered products.¹ While regulatory pathways for these modalities have operated in the United States, Europe, and China for years, public documentation of their adoption across emerging healthcare markets has remained limited.¹

Expanding clinical trials and institutional manufacturing

Clinical trial activity for advanced therapies in Saudi Arabia expanded between 2010 and 2025, concentrating heavily in three therapeutic areas: oncology, hematology, and rare genetic conditions.¹ The concentration reflects local disease burdens and institutional research priorities across national medical facilities.

Domestic research centers have developed local biomanufacturing capabilities to support these treatments rather than relying entirely on imported products. King Faisal Specialist Hospital and Research Centre and King Abdullah International Medical Research Center established internal manufacturing pipelines for CAR-T cell therapies.¹ At the same time, national biobanking programs began supplying biological materials to support translational laboratory studies and early-phase clinical evaluations.¹

The development of internal manufacturing sites aims to address logistical bottlenecks associated with autologous cell therapies, which require collecting patient cells, modifying them in specialized facilities, and reinfusing them under strict timelines. Establishing hospital-based production units allows domestic medical centers to manage cell handling directly.

Infrastructure and reimbursement hurdles

Despite the eight commercial approvals and expanding institutional programs, the researchers identified significant structural hurdles facing the kingdom's advanced therapy sector. The primary constraints involve workforce capacity, specialized good manufacturing practice infrastructure, and long-term reimbursement mechanisms.¹

Biomanufacturing facilities for gene and cell therapies require cleanroom environments, strict contamination controls, and staff trained in specialized cell processing protocols. Building out compliant good manufacturing practice facilities demands sustained capital investment and specialized technical expertise that remains scarce across regional healthcare systems.

Payment structures also present a critical challenge for sustained adoption. Advanced biologic treatments and gene-editing therapies typically carry high upfront acquisition costs. Establishing standardized reimbursement models and coverage pathways within the national healthcare system remains an unresolved operational task as more high-cost therapies secure regulatory clearance.

The study concluded that continued regulatory development, expanded domestic manufacturing capacity, and structured international research partnerships will determine whether the kingdom establishes itself as a regional production and treatment hub for advanced therapeutics.

Reporting note: this piece draws on a review of Saudi Food and Drug Authority regulatory guidelines, clinical trial registrations, and peer-reviewed medical literature from 2010 to 2025 published by researchers led by Mohammed H AlMuhanna in Regenerative Therapy.

Source: Regenerative Therapy via PubMed, August 24, 2026.

References

This article is based on 1 source, listed in the order they are cited.

1. 1 MH Mohammed H AlMuhanna, Maha Alharbi, Alya Aldahash, Rawabi Felemban, Layla Asiri, Manal Alghamdi, Rania Alzahrani, Wadha Aldossary, Naif Alenzi, Maram Almohaywi announcement · 30 Aug 2026 Advanced therapy medicinal products in Saudi Arabia: Regulation and development See the source